Thermedical Successfully Completes Feasibility Study for Treating Cardiac Arrhythmias Using Pulsed Field Ablation in Combination with SERF Ablation
2024年4月23日 - 10:01PM
ビジネスワイヤ(英語)
Thermedical®, a developer of advanced thermal-ablation systems
to treat ventricular arrhythmias, announced today that it has
completed a feasibility study utilizing Pulsed Field Ablation (PFA)
therapy in combination with its SERF Ablation System and Durablate®
Catheter for treating ventricular tachycardia (VT). VT is an
abnormally rapid heart rhythm that is a leading cause of sudden
cardiac death worldwide.
PFA is an emerging technique that harnesses pulsed electrical
field energy to deliver swift and precise tissue ablation in thin
layers of the heart.
“We are encouraged by the results from our pre-clinical
feasibility study evaluating PFA technology integrated into our
SERF Ablation System with the Durablate Catheter. We believe this
combination therapy will show promise in improving the management
of people with VT, potentially offering new hope for people who
live with this challenging condition,” said Michael Curley, Ph.D.,
FHRS, co-founder and CEO of Thermedical. “The incorporation of PFA
into Thermedical’s Durablate Catheter, featuring advanced electrode
configurations, reinforces our commitment to advancing cardiac
ablation technologies. Our Durablate Catheter’s design enables
targeted ablation of previously untreated tissue layers. PFA in
combination with our clinically tested SERF Ablation method may
improve therapeutic outcomes.”
“With this preliminary feasibility study, the SERF system with
the Durablate in combination with PFA therapy showed the potential
to be an efficient option for treating VT,” said Dr. William H.
Sauer, Section Chief, Cardiac Arrhythmia Service of Brigham and
Women’s Hospital. “We are excited about the study’s result and the
potential of PFA therapy to supplement the promise that SERF
Ablation has previously shown.”
Thermedical’s SERF ablation with the Durablate catheter is being
evaluated as a treatment option for patients with ventricular
arrhythmias resistant to antiarrhythmic drugs or standard ablation
procedures.1 SERF ablation provides a new, more efficient form of
biological heat transfer than conventional ablation methods. The
Durablate catheter delivers energy with a high level of accuracy to
treat tissue deeper in the heart wall where life-threatening
arrhythmias that cause VT are often located.
The addition of PFA therapy to SERF ablation may offer a more
complete approach to VT ablation and a practice-changing
technology.
About Thermedical
Thermedical is a privately held company founded by Massachusetts
Institute of Technology (MIT) Hyperthermia Center alumni Michael G.
Curley, Ph.D., and Patrick S. Hamilton, Ph.D., based in Waltham,
Mass. Under a Massachusetts Life Sciences Center Small Business
Matching Grant (SBMG) Award, multiple NIH Small Business Innovation
Research (SBIR) Grants, and Series A venture funding, the company
has developed thermal-ablation systems to treat ventricular
tachycardia (VT) and solid tumors. For more information, visit
www.thermedical.com.
_____________________
1
https://clinicaltrials.gov/study/NCT05337241?term=Thermedical&rank=2
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240423781494/en/
Amy Cook info@thermedical.com